iShares Biotechnology ETF
IBB
IBB
781 hedge funds and large institutions have $7.35B invested in iShares Biotechnology ETF in 2020 Q3 according to their latest regulatory filings, with 97 funds opening new positions, 262 increasing their positions, 229 reducing their positions, and 75 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
781
Holders Change
+18
Holders Change %
+2.36%
% of All Funds
15.8%
Holding in Top 10
17
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-29.17%
% of All Funds
0.34%
New
97
Increased
262
Reduced
229
Closed
75
Calls
$664M
Puts
$986M
Net Calls
-$321M
Net Calls Change
-$200M
Top Buyers
| 1 |
Morgan Stanley
New York
|
$958M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
$1.84B |
| 3 |
N
Natixis
Paris,
France
|
$67.7M |
| 4 |
Squarepoint
New York
|
$29.3M |
| 5 |
EP
Edgestream Partners
Princeton,
New Jersey
|
$25.2M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
$479M |
| 2 |
JPMorgan Chase & Co
New York
|
$291M |
| 3 |
Barclays
London,
United Kingdom
|
$279M |
| 4 |
JG
Jefferies Group
New York
|
$2.42M |
| 5 |
CM
Churchill Management
Los Angeles,
California
|
$161M |
